Sandbox:Roukoz: Difference between revisions
Jump to navigation
Jump to search
Undo revision 1550941 by Roukoz Abou Karam (talk) Tag: Undo |
No edit summary |
||
Line 3: | Line 3: | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diseases | ||
| colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations''' | | colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations''' | ||
! colspan=" | ! colspan="4" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ||
|- | |- | ||
Line 9: | Line 9: | ||
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Skin Examination | ! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Skin Examination | ||
|- | |- | ||
! colspan=" | ! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ||
|- | |- | ||
Line 21: | Line 21: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Areas affected | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Areas affected | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Unique features | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Unique features | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Cutaneous squamous cell carcinoma''' | | style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Cutaneous squamous cell carcinoma''' | ||
Line 38: | Line 37: | ||
* In black individuals, common sites for SCC include the legs, anus, and areas of chronic inflammation or scarring | * In black individuals, common sites for SCC include the legs, anus, and areas of chronic inflammation or scarring | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Keratinocytic dysplasia involving the full thickness of the epidermis without infiltration of atypical cells into the dermis | * Keratinocytic dysplasia involving the full thickness of the epidermis without infiltration of atypical cells into the dermis | ||
Line 55: | Line 53: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 77: | Line 74: | ||
* Human papillomavirus infection | * Human papillomavirus infection | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Develops on sun-exposed areas of the skin. | * Develops on sun-exposed areas of the skin. | ||
* The face (especially the eyelids, nose, cheek, and lower lip), neck, hands, and arms are common sites for involvement | * The face (especially the eyelids, nose, cheek, and lower lip), neck, hands, and arms are common sites for involvement | ||
| style="background: #F5F5F5; padding: 5px;" |a history of rapid growth within weeks favors this diagnosis | | style="background: #F5F5F5; padding: 5px;" |a history of rapid growth within weeks favors this diagnosis | ||
| style="background: #F5F5F5; padding: 5px;" |Keratoacanthomas are keratocytic epithelial tumors that clinically and histologically resemble SCC | | style="background: #F5F5F5; padding: 5px;" |Keratoacanthomas are keratocytic epithelial tumors that clinically and histologically resemble SCC | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 97: | Line 93: | ||
| style="background: #F5F5F5; padding: 5px;" |incidental detection of multiple lesions suspicious for sebaceous tumors during the skin examination may suggest the possibility of the Muir-Torre variant of Lynch syndrome | | style="background: #F5F5F5; padding: 5px;" |incidental detection of multiple lesions suspicious for sebaceous tumors during the skin examination may suggest the possibility of the Muir-Torre variant of Lynch syndrome | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 111: | Line 106: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Blue-red, dome-shaped nodule | | style="background: #F5F5F5; padding: 5px;" |Blue-red, dome-shaped nodule | ||
Line 125: | Line 119: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Cells proliferate downwards through the skin (vertical growth) | | style="background: #F5F5F5; padding: 5px;" |Cells proliferate downwards through the skin (vertical growth) | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 141: | Line 134: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 157: | Line 149: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 171: | Line 162: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* large, hyperchromatic, oval nuclei and little cytoplasm | * large, hyperchromatic, oval nuclei and little cytoplasm | ||
Line 187: | Line 177: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 201: | Line 190: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |The most frequent site of metastasis for cutaneous SCC is the regional lymph nodes; | | style="background: #F5F5F5; padding: 5px;" |The most frequent site of metastasis for cutaneous SCC is the regional lymph nodes; | ||
Line 215: | Line 203: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 229: | Line 216: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Suspected due to evidence of eyelash loss | | style="background: #F5F5F5; padding: 5px;" |Suspected due to evidence of eyelash loss | ||
Line 243: | Line 229: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Develops in skeletal muscles usually | | style="background: #F5F5F5; padding: 5px;" |Develops in skeletal muscles usually | ||
Line 257: | Line 242: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 271: | Line 255: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 285: | Line 268: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Similar to mammary paget disease | | style="background: #F5F5F5; padding: 5px;" |Similar to mammary paget disease | ||
| style="background: #F5F5F5; padding: 5px;" |chronic | | style="background: #F5F5F5; padding: 5px;" |chronic | ||
Line 299: | Line 281: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 313: | Line 294: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Caused by HPV | | style="background: #F5F5F5; padding: 5px;" |Caused by HPV | ||
Line 327: | Line 307: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 341: | Line 320: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 358: | Line 336: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Chronic condition | | style="background: #F5F5F5; padding: 5px;" |Chronic condition | ||
Line 372: | Line 349: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Chronic condition | | style="background: #F5F5F5; padding: 5px;" |Chronic condition | ||
Line 386: | Line 362: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 400: | Line 375: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 414: | Line 388: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 429: | Line 402: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 443: | Line 415: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Not contagious | | style="background: #F5F5F5; padding: 5px;" |Not contagious | ||
Line 457: | Line 428: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Chronic and sometimes accompanied by asthma | | style="background: #F5F5F5; padding: 5px;" |Chronic and sometimes accompanied by asthma | ||
Line 471: | Line 441: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 485: | Line 454: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 499: | Line 467: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 513: | Line 480: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Contains choristomatous tissue | | style="background: #F5F5F5; padding: 5px;" |Contains choristomatous tissue | ||
| style="background: #F5F5F5; padding: 5px;" |Benign congenital tumor | | style="background: #F5F5F5; padding: 5px;" |Benign congenital tumor | ||
Line 528: | Line 494: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Rare autosomal-dominant disorder of the conjunctiva and oral mucosa | | style="background: #F5F5F5; padding: 5px;" |Rare autosomal-dominant disorder of the conjunctiva and oral mucosa | ||
Line 542: | Line 507: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 556: | Line 520: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Containing fibromatous elements | | style="background: #F5F5F5; padding: 5px;" |Containing fibromatous elements | ||
| style="background: #F5F5F5; padding: 5px;" |Arises due to disturbed systemic lipid metabolism | | style="background: #F5F5F5; padding: 5px;" |Arises due to disturbed systemic lipid metabolism | ||
Line 571: | Line 534: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 585: | Line 547: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Typically | | style="background: #F5F5F5; padding: 5px;" |Typically | ||
Line 599: | Line 560: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 613: | Line 573: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 627: | Line 586: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Very rare | | style="background: #F5F5F5; padding: 5px;" |Very rare | ||
Line 641: | Line 599: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Keratosis follicularis | | style="background: #F5F5F5; padding: 5px;" |Keratosis follicularis | ||
Line 655: | Line 612: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Mycosis fungoides | | style="background: #F5F5F5; padding: 5px;" |Mycosis fungoides | ||
Line 669: | Line 625: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 685: | Line 640: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Verrucous carcinoma on the plantar foot | | style="background: #F5F5F5; padding: 5px;" |Verrucous carcinoma on the plantar foot | ||
Line 699: | Line 653: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |also known as giant condyloma acuminatum of Buschke-Loewenstein | | style="background: #F5F5F5; padding: 5px;" |also known as giant condyloma acuminatum of Buschke-Loewenstein |
Revision as of 00:44, 18 February 2019
Diseases | Clinical manifestations | Para-clinical findings | Additional findings | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Skin Examination | ||||||||||
Lab Findings | Histopathology | ||||||||||
Names | Symptom 2 | Symptom 3 | Physical exam 1 | Physical exam 2 | Physical exam 3 | Risk factors | Areas affected | Unique features | |||
Cutaneous squamous cell carcinoma |
|
usually asymptomatic | well-demarcated, scaly patch or plaque | hyperkeratotic, or ulcerative lesions | Lesions are often erythematous but can also be skin colored or pigmented. | Any cutaneous surface, including the head, neck, trunk, extremities, oral mucosa, shoulders, chest and back |
|
|
SCC in situ lesions tend to grow slowly, enlarging over the course of years | ||
Invasive squamous cell carcinoma | Lesions of invasive SCC are often asymptomatic but may be painful or pruritic. | Local neurologic symptoms (eg, numbness, stinging, burning, paresthesias, paralysis, or visual changes) occur in approximately one-third of patients with histologic perineural invasion by the tumor | Well-differentiated lesions usually appear as indurated or firm, hyperkeratotic papules, plaques, or nodules | Poorly differentiated lesions are usually fleshy, soft, granulomatous papules or nodules that lack the hyperkeratosis that is often seen in well-differentiated lesions | Poorly differentiated tumors may have ulceration, hemorrhage, or areas of necrosis. | ||||||
Keratoacanthoma | keratocytic epithelial tumors | Initial lesion: small pink macule
Later: papular quality and eventually forms a circumscribed nodule. |
The periphery of the nodule tends to be skin-colored or mildly erythematous and may have accompanying telangiectasias | The center of the nodule typically demonstrates a prominent keratinous core. |
|
|
a history of rapid growth within weeks favors this diagnosis | Keratoacanthomas are keratocytic epithelial tumors that clinically and histologically resemble SCC |
| ||
Muir-Torre | incidental detection of multiple lesions suspicious for sebaceous tumors during the skin examination may suggest the possibility of the Muir-Torre variant of Lynch syndrome | ||||||||||
Merkel cell carcinoma | Starts on areas of skin exposed to the sun | Single pink, red, or purple shiny bump | Painless | Blue-red, dome-shaped nodule | |||||||
Nodular malignant melanoma | Lump that has been rapidly growing over the past weeks | Cells proliferate downwards through the skin (vertical growth) |
| ||||||||
Amelanotic melanoma | Color usually pink, purple or normal skin color | Usually have an asymmetrical shape with an irregular border | Red, nonspecific lesion with slightly elevated borders |
| |||||||
Basal cell carcinoma | Coarse scale lesion | ||||||||||
Superficial basal cell carcinoma | Scaly patch | Erythematous lesion |
|
||||||||
Nodular basal cell carcinoma | Pearly papule with telangiectasias | ||||||||||
Cutaneous metastases of internal malignancy | Other sites lungs, liver, brain, skin, or bone. | The most frequent site of metastasis for cutaneous SCC is the regional lymph nodes; | |||||||||
Benign Skin Lesions | |||||||||||
Sebaceous cell carcinoma | Yellow-nodule | Suspected due to evidence of eyelash loss | |||||||||
Rhabdomyosarcoma | Bulging of the eye or a swollen eyelid | Develops in skeletal muscles usually | |||||||||
Actinic keratoses | Pain | Hyperkeratosis | Erythema | less pigmentation, and tend to be somewhat smaller in size. | |||||||
Prurigo nodules | Hard lesion | Itchy lumps | |||||||||
Paget disease | Eczema-like rash of the skin | Around the genital regions of males and females. | Similar to mammary paget disease | chronic | |||||||
Inflamed seborrheic keratosis | Waxy, "stuck on," often hyperkeratotic appearance | ||||||||||
Viral warts | Verrucous lesion | Caused by HPV | |||||||||
Pyogenic granuloma | Rapidly growing | Red, dome-shaped | Friable papule with a collarette of scale | ||||||||
Bowenoid papulosis | multiple, red- to brown-colored, small papules that |
| |||||||||
Nummular eczema | Itchy lesions | Coin shaped spots | Chronic condition | ||||||||
Psoriasis | Flaking, inflammation | Thick, white, silvery, or red patches of skin | Chronic condition | ||||||||
Pyoderma gangrenosum | Purulent ulcer | Ragged and violaceous border | |||||||||
Venous stasis ulcers | |||||||||||
Traumatic ulcers | |||||||||||
Sebaceous Hyperplasia | Lesions can be single or multiple lesions |
Yellowish, soft, small papules on the face |
Usually on the nose, cheeks, and forehead | ||||||||
Allergic Contact Dermatitis | Itchy rash | Red rash | Not contagious | ||||||||
Atopic Dermatitis | Itchy rash | Fever | Red rash | Chronic and sometimes accompanied by asthma | |||||||
Atypical Fibroxanthoma | Erythematous, dome-shaped papule | ||||||||||
Nevus | |||||||||||
Chemical Burns | |||||||||||
Limbal Dermoid | Contains choristomatous tissue | Benign congenital tumor | |||||||||
Benign hereditary intraepithelial dyskeratosis | Rare autosomal-dominant disorder of the conjunctiva and oral mucosa | ||||||||||
primary acquired melanosis | |||||||||||
Fibrous xanthoma | Containing fibromatous elements | Arises due to disturbed systemic lipid metabolism | |||||||||
Inflamed seborrheic keratosis | Inflamed and hyperpigmented | On dermatoscopic evaluation, presence of horned cysts and hairpin-shaped blood vessels | |||||||||
Juvenile xanthogranuloma | Reddened, yellowish-tan color of lesions | Slightly raised bumps | Typically | ||||||||
Cutaneous fungal infections | |||||||||||
Desmoplastic trichoepithelioma | |||||||||||
Adnexal carcinoma | Very rare | ||||||||||
Darier disease | Keratosis follicularis | ||||||||||
Cutaneous T-cell lymphoma | Mycosis fungoides | ||||||||||
Marjolin's ulcer | Lesions in sites of chronic wounds and scars | Excessive granulation tissue, | Rolled or everted wound margins | Bleeding on touch |
| ||||||
Epithelioma cuniculatum | Increased size | Verrucous carcinoma on the plantar foot | |||||||||
Anogenital | also known as giant condyloma acuminatum of Buschke-Loewenstein |
SCC in situ: Frequently, there is associated thickening of the epidermis (acanthosis), as well as hyperkeratosis and parakeratosis of the stratum corneum. In contrast to SCC in situ, actinic keratoses demonstrate only partial-thickness epidermal dysplasia.